IMMUNE EFFECTOR MECHANISMS IN EBV CARRYING PATIENTS

该项目涉及EB病毒感染的细胞和细胞之间的相互作用。 正常和免疫缺陷者宿主免疫系统。 的改进的 了解这个复杂的系统，有必要扩大我们的 关于病毒与不同宿主细胞相互作用的知识， 体外和体内，以及病毒感染细胞之间的相互作用 和主持人 该项目旨在分析某些问题， 这两个层面，以相互关联的方式。 该项目由以下部分组成： I.病毒-细胞-宿主系统分析 二.临床相关研究 抗原分析将集中在新检测到的膜的作用 转化的、增殖的、非病毒生产者表面的抗原 细胞，其免疫识别，其遗传决定机制（在 与病毒基因组的关系）以及阻断抗体的意义 效应器分析将剖析各种 BL和NPC中的淋巴细胞亚型和介质， 没有携带EBV的淋巴组织增生性疾病，以及健康对照。 在靶细胞水平上，将继续关注 自发或诱导的B细胞分化， 非免疫宿主控制。 临床相关研究将集中在单克隆与多克隆 移植淋巴瘤中EBV转化的B细胞增殖的性质， 以及XLP中的淋巴增生性疾病，因为它与EBV有关。 在 效应水平，我们将继续调查损害 不同的效应器和抑制在免疫缺陷中的作用 携带EBV的淋巴瘤，与免疫缺陷状态（HD和 NHL、AT），EBV转化细胞的控制受损（如 致敏和抗体形成解离成EBNA， 一方面，另一方面，EA/VCA），但不携带EBV 淋巴组织增生性疾病 将对艾滋病前期进行专门的效应细胞和靶细胞研究 淋巴瘤

This project deals with the interactions between EBV-infected cells and the host immune system in normal and immunodefective persons. For an improved understanding of this complex system, it is necessary to broaden our knowledge both on the interaction of the virus with different host cells in vitro and in vivo, and on the interplay between the virally infected cells and the host. This project aims at the analysis of certain questions at both levels, in a mutually interrelated way. The project consists of the following parts: I. Analysis of the virus-cell-host system II. Clinically related studies Antigenic analysis will focus on the role of the newly detected membrane antigen on the surface of transformed, proliferating, non-virus producer cells, its immune recognition, its genetic determination mechanism (in relation to the viral genome) and the significance of blocking antibodies directed against it. Effector analysis will disssect the role of various lymphocyte subtypes and mediators in BL and NPC, immunodefectives with and without EBV-carrying lymphoproliferative disease, and in healthy controls. At the target cell level, continued attention will be given to the role of spontaneous or induced B-cell differentiation by immunological and non-immunological host control. The clinically related studies wil focus on the monoclonal vs. polyclonal nature of EBV-transformed B-cell proliferation in transplant lymphomas, and lymphoproliferative disease in XLP, as it relates to EBV. At the effector level, we shall continue to investigate the impairment of different effectors and the role of suppression in immunodeficient EBV-carrying lymphomas, as contrasted to immunodefective states (HD and NHL, AT) with an impaired control of EBV-transformed cells (as indicated by the dissociation of sensitization and antibody formation into EBNA, on the one hand, and to EA/VCA on the other), but without EBV carryig lymphoproliferative disease. A special effector and target cell study will be carried out on pre-AIDS lymphomas.